Rna vector therapy method

Abstract

The innovative treatment method described here utilizes configurable microscopic medical payload delivery devices to act as a transport vector to deliver a wide variety of cellular ribonucleic acid molecules to specific types of cells in the body. Utilizing probes on the exterior of the transport devices, the transport devices locate a specific type of cell in the body. Once a specific target cell type has been encountered, the configurable microscopic medical payload delivery devices insert their payload of cellular ribonucleic acid molecules into the target cells. By delivering cellular ribonucleic acid molecules into specific cells a wide variety of protein deficiencies are correctable, gene expression is capable of being modulated, and telomere synthesis is enhanced.

1 . A method for inserting cellular ribonucleic acid molecules into specific cells comprising:
 (a) providing a quantity of protein shells,   (b) covering said protein shells with an exterior envelope,   (c) fixing a quantity of exterior probes to said exterior envelope, and   (d) positioning a quantity of cellular ribonucleic acid molecules inside the cavity created by the innermost said protein shell,   whereby said quantity of protein shells covered with said exterior envelope with said quantity of exterior probes affixed to said exterior envelope, with said cellular ribonucleic acid molecules carried in said cavity created by said inner most protein shell, engages said specific types of cells and inserts said cellular ribonucleic acid molecules into said specific cells in order to produce a medically beneficial effect,   whereby said exterior probes are intended to engage specific cell-surface receptors on said specific cells,   whereby said interior shells are versatile enough in their construction to carry within said cavity created by said innermost said protein shell a wide variety of cellular ribonucleic acid molecules to said specific cells,   whereby inserting said cellular ribonucleic acid molecules into said specific types of cells will facilitate the successful management of protein deficient states inside said specific cells.   
     
     
         2 . The method for inserting cellular ribonucleic acid molecules into specific cells in  claim 1  wherein said external envelope is selected from the group consisting of a lipid layer, a lipid bilayer, a protein matrix, a lipid layer affixed to a protein matrix, and a lipid bilayer affixed to a protein matrix. 
     
     
         3 . The method for inserting cellular ribonucleic acid molecules into specific cells in  claim 1  wherein said external envelope is comprised of a quantity of lipid layers and a quantity of protein matrix shells. 
     
     
         4 . The quantity of lipid layers in  claim 3  wherein said quantity of lipid layers is a quantity of phospholipid layers. 
     
     
         5 . The method for inserting cellular ribonucleic acid molecules into specific cells in  claim 1  wherein said internal shells is comprised of a quantity of nested sphere-like concentric protein matrix shells. 
     
     
         6 . The method for inserting cellular ribonucleic acid molecules into specific cells in  claim 1  wherein said exterior probes are comprised of a quantity of protein structure probes and a quantity of glycoprotein probes. 
     
     
         7 . The protein structure probes in  claim 6  wherein said protein structure probes are comprised of a segment of said protein structure probes which extends outward and away from said exterior envelope, which is attached to a segment of said protein structure probes which is embedded in said exterior envelope to hold said protein structure probes affixed to said exterior envelope,
 whereby said segment of said protein structure probes which extends outward and away from said exterior envelope is intended to engage said specific cell-surface receptor located on said specific cells. 
 
     
     
         8 . The protein structure probes in  claim 6  wherein said protein structure probes are comprised of a plurality of protein structure probes,
 whereby, at least two differing configurations of said protein structure probes may be needed to successfully engage said specific cells with one type of configuration of said protein structure probes engaging one type of said specific cell-surface receptor, while a differing type of configuration of said protein structure probes is required to engage a differing type of said specific cell-surface receptor in order for said quantity of said cellular ribonucleic acid molecules to be inserted into said specific cells. 
 
     
     
         9 . The glycoprotein probes in  claim 6  wherein said glycoprotein probes are comprised of a protein segment which extends outward and away from said exterior envelope, which is attached to a carbohydrate segment, said carbohydrate segment embedded in said exterior envelope to hold said glycoprotein probe affixed to said exterior envelope,
 whereby said protein segment which extends outward and away from said exterior envelope is intended to engage said specific cell-surface receptor on said specific cells. 
 
     
     
         10 . The glycoprotein probes in  claim 6  wherein said glycoprotein probes are comprised of a plurality of glycoprotein probes,
 whereby, at least two differing configurations of said glycoprotein probes may be needed to successfully engage said specific cells with one type of configuration of said glycoprotein probes engaging one type of said specific cell-surface receptor, while a differing type of configuration of said glycoprotein probes is required to engage a differing type of said specific cell-surface receptor in order for said quantity of cellular ribonucleic acid molecules to be inserted into said specific cells. 
 
     
     
         11 . The method for inserting cellular ribonucleic acid molecules into specific cells in  claim 1  wherein said cellular ribonucleic acid molecules are comprised of a quantity of messenger ribonucleic acid molecules and a quantity of non-coding ribonucleic acid molecules. 
     
     
         12 . The non-coding ribonucleic acid molecules in  claim 11  wherein said non-coding ribonucleic acid molecules are comprised of a quantity of transport ribonucleic acid molecules, a quantity of ribosomal ribonucleic acid molecules, a quantity of small nuclear ribonucleic acid molecules, a quantity of small nucleolar ribonucleic acid molecules, a quantity of signal recognition particle ribonucleic acid molecules, a quantity of antisense ribonucleic acid molecules, a quantity of micro ribonucleic acid molecules, a quantity of small interfering ribonucleic acid molecules, a quantity of Y ribonucleic acid molecules, and a quantity of telomerase ribonucleic acid molecules. 
     
     
         13 . The messenger ribonucleic acid molecules in  claim 11  wherein said messenger ribonucleic acid molecules are comprised of a quantity of naturally occurring messenger ribonucleic acid molecules and a quantity of modified messenger ribonucleic acid molecules. 
     
     
         14 . The modified messenger ribonucleic acid molecules in  claim 13  wherein said modified ribonucleic acid molecules is comprised of a quantity of messenger ribonucleic acid molecules modified in the 3′ untranslatable region, a quantity of messenger ribonucleic acid molecules modified in the coding region, and a quantity of ribonucleic acid molecules modified in the 5′ untranslatable region,
 whereby said modification of said messenger ribonucleic acid molecules in said 3′ untranslatable region results in said modified messenger ribonucleic acid molecules resisting degradation by cellular enzymes without compromising the functionality of said modified messenger ribonucleic acid molecules, which results in enhance protein production by said ribosomes to produce a medically therapeutic treatment, 
 whereby said modification of said modified messenger ribonucleic acid molecules occurring in said coding region results in production of improved proteins, 
 whereby said modification of said modified messenger ribonucleic acid molecules in said 5′ untranslatable region results in an enhanced recognition of said modified ribonucleic acid molecules by ribosomes and encourages said modified ribonucleic acid molecules to be translated by said ribosomes. 
 
     
     
         15 . The modified messenger ribonucleic acid molecules in  claim 13  wherein said modified ribonucleic acid molecules is comprised of a quantity of messenger ribonucleic acid molecules, which are comprised of a quantity of nucleotides modified in the 3′ untranslatable region, a quantity of nucleotides modified in the coding region, and a quantity of nucleotides modified in the 5′ untranslatable region,
 whereby said modification of said messenger ribonucleic acid molecules in said 3′ untranslatable region results in said modified messenger ribonucleic acid molecules resisting degradation by cellular enzymes without compromising the functionality of said modified messenger ribonucleic acid molecules, which results in enhance protein production by said ribosomes to produce a medically therapeutic treatment, 
 whereby said modification of said modified messenger ribonucleic acid molecules occurring in said coding region results in production of improved proteins, 
 whereby said modification of said modified messenger ribonucleic acid molecules in said 5′ untranslatable region results in an enhanced recognition of said modified ribonucleic acid molecules by ribosomes and encourages said modified ribonucleic acid molecules to be translated by said ribosomes.